Andrea Cusack discusses how, by using bottom-up nanotechnology techniques, efficiencies can be found both in the development of new chemical entities and in the repurposing of existing drugs, and how these efficiencies translate into reduced energy requirements and therefore more sustainable industry practices.
TFF AND UNION AGREE LICENSING PACT FOR TFF TECHNOLOGY WITH NICLOSAMIDE FOR THE TREATMENT OF COVID-19
Adare Pharma's Maria Flynn talks with ONdrugDelivery about trends in the oral drug development and delivery space, completing the Orbis Biosciences acquisition during a global pandemic, and how the excellent technology portfolio and strategic fit between Orbis and Adare form part of the combined organisation’s unique story.
Dr Batalla introduces the company and describes its Proteoral® technology for the oral delivery of proteins to the bloodstream, therapeutic applications, and products to date. Panarum is an Argentine company and this interview is presented here in Spanish and English, an exciting first for ONdrugDelivery!
Stabilitech Recognised by WHO, seeks £6m funding to make oral SARS-COV-2 vaccine available by end of 2020
Stabilitech Biopharma, which is developing OraPro-COVID-19, an oral coronavirus vaccine, has been formally recognised on the international stage by the WHO as a vaccine developer, and seeks £6 million to fund clinical trials and manufacturing required to make the vaccine available by the end of 2020.
Martti Hedman, Chief Executive of Colorcon, has released a statement in which he confirmed that Colorcon is continuing its business activities, which had been categorised as essential and life sustaining by authorities around the world. He noted that Colorcon materials and coatings are used in some of the drugs that are being evaluated for use to treat COVID-19.
Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19
Sarah Trenfield and Abdul Basit look at the potential applications of 3D-printing technology to create personalised drug therapies in fields such as multiple drug therapy and paediatric/geriatric care and introduce FabRx’s 3D-printing system, which can produce formulations to suit a variety of situations.